TABLE 1.
Age-adjusted baseline characteristics across tertiles of Lp-PLA2 activity among 777 female type 2 diabetic subjects from the NHS and 740 male type 2 diabetic subjects from the HPFS
| Tertile of Lp-PLA2 |
||||||
|---|---|---|---|---|---|---|
| Tertile 1 |
Tertile 2 |
Tertile 3 |
||||
| Men | Women | Men | Women | Men | Women | |
| Lp-PLA2 mean (nmol · min−1 · ml−1) | 126.2 | 119.9 | 159.3 | 157.3 | 199.7 | 200.0 |
| Lp-PLA2 range | 60.4–146.0 | 56.4–141.2 | 146.1–173.1 | 141.3–172.5 | 173.2–391.2 | 172.6–343.0 |
| Age at baseline (years) | 61.4 | 57.0 | 62.1 | 58.3 | 61.4 | 58.7 |
| BMI (kg/m2) | 27.9 | 29.4 | 27.6 | 30.4 | 27.8 | 30.4 |
| Physical activity (MET) | 28.9 | 43.7 | 28.9 | 20.8 | 27.4 | 28.1 |
| Current smoker (%) | 6.2 | 9.9 | 7.0 | 10.5 | 8.4 | 21.1 |
| Regular aspirin use (%) | 37.6 | 24.6 | 37.1 | 21.4 | 31.2 | 24.2 |
| Duration of diabetes (years) | 7.8 | 9.4 | 7.9 | 8.2 | 6.7 | 6.2 |
| Family history of CHD (%) | 36.3 | 23.0 | 35.0 | 21.3 | 35.4 | 28.3 |
| History of hypertension (%) | 42.6 | 55.1 | 45.2 | 62.4 | 45.9 | 64.4 |
| History of high serum cholesterol (%) | 33.3 | 47.0 | 39.5 | 52.9 | 49.6 | 51.8 |
| Cholesterol-lowering medication use (%) | 5.9 | 3.9 | 8.5 | 4.3 | 6.2 | 4.2 |
| Postmenopausal hormone use (%) | N/A | 36.1 | N/A | 23.0 | N/A | 18.3 |
| Insulin use (%) | 18.8 | 20.1 | 19.9 | 21.1 | 15.5 | 17.7 |
| Alcohol (g/day) | 8.7 | 3.4 | 8.9 | 2.5 | 9.1 | 3.4 |
| C-reactive protein (median; mg/dl) | 1.4 | 5.0 | 1.9 | 4.8 | 1.8 | 5.4 |
| A1C (%) | 7.4 | 6.7 | 7.4 | 6.8 | 7.2 | 7.0 |
| Intercellular adhesion molecule (ng/ml) | 344.7 | 290.2 | 351.8 | 303.4 | 370.1 | 347.2 |
| Triglycerides (mg/dl)* | 189.4 | 174.5 | 169.0 | 185.2 | 193.3 | 203.1 |
| LDL cholesterol (mg/dl) | 110.3 | 122.6 | 127.8 | 140.5 | 141.4 | 155.0 |
| HDL cholesterol (mg/dl) | 43.3 | 59.1 | 41.0 | 51.0 | 37.9 | 46.2 |
*Triglycerides based on 406 men and 527 women with fasted blood samples.